Current disease status-Recurrent myeloma Posts on Medivizor
Navigation Menu

Current disease status-Recurrent myeloma Posts on Medivizor

Long-term outcomes of daratumumab with lenalidomide and dexamethasone in relapsed or unresponsive multiple myeloma

Posted by on Apr 16, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study compared the use of lenalidomide (Revlimid) and dexamethasone (Decadron) alone and with daratumumab (Darzalex) in patients with relapsed or unresponsive multiple myeloma (MM). The study showed that patients receiving all three drugs had better treatment response and survival. Some background MM is a type of cancer that affects...

Read More

Evaluating a triplet regimen for patients with relapsed or refractory MM after lenalidomide therapy

Posted by on Oct 1, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study examined if PBD (pomalidomide, bortezomib, dexamethasone) was safe and effective in patients with multiple myeloma after lenalidomide (Revlimid) treatment. The authors concluded that pomalidomide improved survival without tumor growth or spread but increased side effects. Some background...

Read More

Does age influence the safety and effectiveness of stem cell treatment for patients with multiple myeloma?

Posted by on Jul 14, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study examined the safety and effectiveness of stem cell transplantation (SCT) in elderly patients with multiple myeloma (MM) aged 65 or older compared to younger patients. The authors concluded that SCT was equally as safe and effective for patients in both age groups. Some background Multiple myeloma is a complex type of...

Read More

Evaluating outcomes after salvage stem cell transplantation for patients with recurrent multiple myeloma

Posted by on Apr 30, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the outcomes of patients with recurrent multiple myeloma (MM) after a stem cell transplant (SCT). This study concluded that these patients had a lower quality of life up to 2 years after treatment. Some background Multiple myeloma is a type of cancer of the bone marrow that can lead to abnormal immune cells. For...

Read More

Evaluating carfilzomib plus dexamethasone for relapsed or refractory multiple myeloma

Posted by on Mar 10, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the impact of carfilzomib (Kyprolis) and dexamethasone (Decadron) on quality of life for patients with relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study concluded that patients treated with this combination had a higher quality of life. Some background MM is a...

Read More

Searching for patients to try a new therapy for non-responsive multiple myeloma.

Posted by on Feb 23, 2019 in Multiple Myeloma | 0 comments

In a nutshell This trial will investigate the effects of bb2121 in patients with non-responsive multiple myeloma (MM) who have progressed after standard treatment. The percentage of patients who respond and the percentage of patients who respond completely will be the main measures in this study. This study will take place in the United States and...

Read More

Evaluating ixazomib, cyclophosphamide and dexamethasone treatment for relapsed/refractory multiple myeloma

Posted by on Dec 22, 2018 in Multiple Myeloma | 0 comments

In a nutshell This article investigated the safety and effectiveness of combining ixazomib (Ninlaro), cyclophosphamide (Cytoxan) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the combination treatment is safe and gave...

Read More

How does elotuzumab affect pain and quality of life in non-responsive multiple myeloma?

Posted by on Nov 19, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the effects of adding elotuzumab to lenalidomide and dexamethasone to treat un-responsive multiple myeloma. The main finding was that patients treated with elotuzumab responded better to lenalidomide and dexamethasone. Some background Many patients respond well to treatment for multiple myeloma (MM). However some...

Read More

The safety of elotuzumab, lenalidomide and dexamethasone in unresponsive multiple myeloma.

Posted by on Oct 18, 2018 in Multiple Myeloma | 0 comments

In a nutshell This paper compared the safety and effectiveness of elotuzumab (Empliciti) plus lenalidomide (Revlimid) and dexamethasone (Decadron) with lenalidomide and dexamethasone in unresponsive multiple myeloma. It was found that elotuzumab plus lenalidomide and dexamethasone was more effective than lenalidomide and dexamethasone alone. Some...

Read More